fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Peg-electrolytes

2 general benefit · 1 not a benefit

JampLyte · DIN 02378329 · · Pd-4L Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
JampLyte · DIN 02378329 Manufacturer: Jamp Pharma Corporation; listing date 2026-06-30 Health Canada: Marketed since 2025-06-17 · brand JAMPLYTE · ATC A06AD65 MACROGOL, COMBINATIONS · form Powder · route Oral · ingredients SODIUM CHLORIDE 5.84 G/280G, POLYETHYLENE GLYCOL 3350 238.2 G/280G, SODIUM BICARBONATE 6.76 G/280G, POTASSIUM CHLORIDE 3.04 G/280G, SODIUM SULFATE 22.96 G/280G · company Jamp pharma corporation · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

JampLyte: Formulary list price $16.46 per unit (the source does not state the unit; exact figure $16.4640). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02378329)

Source record
DIN 02378329: JampLyte Raw flags: sec3=Y Item: 401200040; group id 549; item number 1481; lccId None; manufacturer id JPC Source form: Pd-4L Pk; strength: None Recorded listing: General benefit Source prices (unrounded): $16.4640; ministry $16.4640 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02378329 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86414
Interchangeable products
Colyte · DIN 00677442 · not recorded PegLyte Powder · DIN 00777838 · $16.4640
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02378329
Shortage record checked October 6, 2026

PegLyte Powder · DIN 00777838 · · Pd-4L Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
PegLyte Powder · DIN 00777838 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1996-10-01 Health Canada: Marketed since 2013-05-22 · brand PEGLYTE POWDER · ATC A06AD10 MINERAL SALTS IN COMBINATION · form Powder for solution · route Oral · ingredients MACROGOL 238.18 G/BOTTLE, SODIUM CHLORIDE 5.85 G/BOTTLE, SODIUM SULFATE 22.96 G/BOTTLE, POTASSIUM CHLORIDE 3.05 G/BOTTLE, SODIUM BICARBONATE 6.76 G/BOTTLE · company Pendopharm division of pharmascience inc · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

PegLyte Powder: Formulary list price $16.46 per unit (the source does not state the unit; exact figure $16.4640). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00777838)

Source record
DIN 00777838: PegLyte Powder Raw flags: sec3=Y Item: 401200040; group id 549; item number 1481; lccId None; manufacturer id PEN Source form: Pd-4L Pk; strength: None Recorded listing: General benefit Source prices (unrounded): $16.4640; ministry $16.4640 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00777838 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9351
Interchangeable products
Colyte · DIN 00677442 · not recorded JampLyte · DIN 02378329 · $16.4640
Shortage status: resolved shortage (ended January 13, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00777838
Shortage record checked October 6, 2026

Colyte · DIN 00677442 · · Pd-4L Pk

Listed, not a benefitMarketed · checked October 5, 2026
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Colyte · DIN 00677442 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1996-10-01 Health Canada: Marketed since 2013-04-01 · brand COLYTE · ATC A06AD65 MACROGOL, COMBINATIONS · form Powder for solution · route Oral, Nasogastric · ingredients SODIUM CHLORIDE 20.87 MG/G, SODIUM SULFATE 81.2 MG/G, SODIUM BICARBONATE 24.02 MG/G, POLYETHYLENE GLYCOL 3350 857.69 MG/G, POTASSIUM CHLORIDE 10.65 MG/G · company Pendopharm division of pharmascience inc · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

Colyte: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00677442)

Source record
DIN 00677442: Colyte Raw flags: notABenefit=Y, sec3=Y Item: 401200040; group id 549; item number 1481; lccId None; manufacturer id PEN Source form: Pd-4L Pk; strength: None Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00677442 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6616
Interchangeable products
JampLyte · DIN 02378329 · $16.4640 PegLyte Powder · DIN 00777838 · $16.4640
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00677442
Shortage record checked October 6, 2026
Other drugs in the same formulary class (40:12 Replacement Agents) and how they are covered

Matched class: 40:12 Replacement Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ELECTROLYTE & DEXTROSE 40:12 Replacement Agents

ELECTROLYTE & DEXTROSE

· 2 products · General benefit · strengths: · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 40:12
Full class listing Related classes: 40:18 Potassium-Removing Resins, 40:28 Diuretics, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: constipation
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: BISACODYL BISACODYL · General benefit INDICATIONS AND CLINICAL USE DULCOLAX is indicated for: • Relief of occasional constipation • Under medical supervision, for the preparation of diagnostic procedures, in pre- and postoperative treatment, and in conditions which require defecation to be facilitated. PM: https://pdf.hres.ca/dpd_pm/00076868.PDF; date November 3, 2022; DIN 00003875; fetched 2026-09-10 Product monograph PRUCALOPRIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS RESOTRAN® (prucalopride succinate tablets) is indicated for: • The treatment of chronic idiopathic constipation in adult female patients in whom laxatives failed to provide adequate relief. PM: https://pdf.hres.ca/dpd_pm/00073288.PDF; date NOV 08, 2023; DIN 02377012; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults Colyte® (PEG 3350 and Electrolytes) is indicated for:  bowel cleansing prior to colonoscopy or barium enema x-ray examination or surgical procedures requiring a clean colon.  the treatment of constipation https://pdf.hres.ca/dpd_pm/00061814.PDF PM date: March 25, 2021 Source product: COLYTE; DIN 00677442; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Colyte: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026